Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells Disease

Sickle Cells Disease Clinical Trial

— DREVAC  

Official title:

Study of the Immunogenicity of a Prime Boost Vaccination Strategy Combining Conjugated Anti-pneumococcal and Polysaccharide Anti-pneumococcal Vaccine Compared to Polysaccharide Anti -Pneumococcal Vaccine Alone in Patients With Sickle Cells Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02274415
• Other study ID #: AOM10028
• Secondary ID: P100105
• Status: Completed
• Phase: Phase 2
• Start date: September 16, 2013
• Est. completion date: April 10, 2019

Study information

• Verified date: October 2017
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Streptococcus pneumoniae is the major cause of bacterial infection in patients with sickle cells disease. The 23-valent pneumococcal polysaccharide vaccine (PSV) is supposed to be poorly immunogenic in these patients. We want to evaluate whether a prime with a 13-valent pneumococcal conjugate vaccine (PCV), able to induce immunologic memory, would improve the immune response against SP polysaccharides (SPP). Primary objective: To evaluate and compare the specific antibody response to a prime-boost vaccine strategy combining PCV prime at W0 followed by the administration of PSV boost at W4, to the administration of PSV alone at W4 in patients with sickle cells disease. Secondary objectives: Evaluation and comparison of the specific antibody response to the thirteen pneumococcal serotypes shared by the PCV and PSV vaccines, 4 weeks after the single PSV vaccination for patients from Group 1 or 4 weeks after the boost PSV vaccination for patients from group 2. Evaluation of the duration of the specific antibody response at W24 and 96. Evaluation of the T CD4 lymphocyte response to the CRM 197 protein. Safety of the vaccines. Study Design: Randomised, monocentric, controlled phase II study of the immunological efficacy of a prime boost strategy combining the sequential administration of the PCV and PSV, compared to the administration of the PSV alone. 180 adults patients with sickle cells disease will be included. The primary endpoint : proportion of responders at W8 to at least 10 of thirteen serotypes. Secondary endpoints : Proportion of responders at W8 according to 4 categories of responders: 5-7; 3-4; 2-1 and 0. Evaluation of the pneumococcal opsonophagocytic activity (OPA) at baseline and W8 for each serotype, defined as the proportion of patients with OPA > 1:8 geometric mean of the specific antibody titers proportion of patients who experienced an increase of specific antibody levels 1 g/ml. Evaluation of the priming effect of the PCV vaccine in the group 1. Duration of the specific antibody responses at week 24 and W96. CD4 T lymphocyte responses to the CRM 197 protein (proliferative and cytokine production) at weeks 0, 8 and 12. Safety of the vaccines frequency of Streptococcus pneumoniae infections. Statistical Considerations: With a sample size of 180 patients, and a randomization ration of 1:1, the study will have a power of at least 90% to show a difference of 25% category between the group receiving PCV and PSV vs the group receiving PSV alone (two-sided type I error = 5%). The primary comparison between both groups will be performed using a Chi2 test for independent groups or a Fisher exact test where appropriate.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 116
• Est. completion date: April 10, 2019
• Est. primary completion date: September 18, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years
• Adult patient with sickle cell anemia (SS homozygous, SC heterozygous compound Sbetathal heterozygous)

Exclusion Criteria:

• Heterozygous sickle cell anemia
• Active infection
• Hypersensitivity known or suspected to Prevenar 13® or to Pneumo 23® or to any of the excipients included in the formulation or in the administration system
• Coagulation abnormality indicating against an intramuscular injection (Platelets <50 000 or TP<50%)
• Current chemotherapy or radiotherapy, except for using Siklos®/Hydrea® in the context of sickle cell anemia
• Vaccination whatever in the last 2 months before the protocol vaccination, except influenza vaccination (within 30 days)
• Vaccination whatever, provided in the first 2 months following the protocol vaccinations, except influenza vaccination (within the first month following the protocol vaccinations))
• History of pneumococcal vaccination with Pneumo 23® in the previous year
• End-stage renal failure(dialyzed patient, clearance<10ml/mn)
• HIV infection at baseline
• Pregnancy or breastfeeding (A dosage of betaHCG will be conducted for women in childbearing age),contraception recommendation the first 8 weeks of the test for women in childbearing age
• Participation in a clinical research protocol using a drug within the month prior to inclusion.
• No medical assurance
• Adults under tutelage

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Invasive Pneumococcal Infections
• Pneumococcal Infections
• Sickle Cells Disease

Intervention

Biological:
• Vaccination with the combined vaccine (Prevenar13 ®)

• Vaccination with the polysaccharide vaccine (Pneumo 23 ®)

Locations

Country	Name	City	State
France	Henri Mondor Hospital	Creteil

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the proportion of responders at least to 10 of thirteen serotypes	A responder is defined by a rise least two fold from baseline) of antibody titers specific to pneumococcal serotypes;	at Week 8
Secondary	Proportion of responders according to 4 categories of responders: 5-7; 3-4; 2-1 and 0.	Response is defined as fold rise of antibody titers (W8 to baseline)	at Week 8
Secondary	Evaluation of the pneumococcal opsonophagocytic activity (OPA) for each serotype,	defined as the proportion of patients with OPA > 1:8.	at baseline and Week 8
Secondary	The antibody response of the conjugate vaccine	The antibody response to the 13 serotypes of the conjugate vaccine in terms of geometric mean of the specific antibody titers (µg/ml)	at week 4
Secondary	The antibody response to the 13 serotypes of the conjugate vaccine in terms of proportion of patients		at week 4
Secondary	In the group 1 antibodies titers (µg/ml)		at week 24 and W96
Secondary	Number of T CD4 cells responsive to the CRM 197 protein (proliferative and cytokine production) in the two groups of the study		at weeks 0, 8 and 12.
Secondary	Number of Streptococcus pneumoniae infections	Number of Streptococcus pneumoniae infections (bacteremia, meningitis, pneumonia, sinusitis, upper respiratory tract infections)	between baseline and W96